Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is primarily used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure disorders.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Adjunctive treatment of other seizure disorders where oral therapy is suitable.
## Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):** The recommended starting dose is 5 mg twice daily. Titrate upwards by 5-10 mg per day every week to a maximum of 20 mg twice daily, based on clinical response and tolerability.
* **Other Seizure Disorders:** Dosing varies. A common starting dose is 5 mg twice daily, with titration up to a maximum of 20 mg twice daily.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS) (2 years and older):**
* Starting dose: 2.5 mg twice daily.
* Titration: Increase by 2.5-5 mg per day every week to a target dose of 0.5-1 mg/kg/day, divided into two doses.
* Maximum dose: 10 mg twice daily (for patients <30 kg) or 20 mg twice daily (for patients ≥30 kg).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Lower doses may be indicated.
* **Renal Impairment:** Use with caution. Lower doses may be indicated.
* Concomitant use with strong CYP3A4 or CYP2C19 inhibitors: May require dose reduction.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, aggression, irritability, and difficulty with coordination. Serious adverse effects include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, and withdrawal symptoms upon discontinuation.
## Key Drug Interactions
* **CNS Depressants:** Increased risk of sedation and respiratory depression (e.g., alcohol, opioids, other benzodiazepines, barbiturates).
* **CYP3A4 Inhibitors:** Increased clobazam levels (e.g., ketoconazole, itraconazole, ritonavir).
* **CYP2C19 Inhibitors:** Increased clobazam levels (e.g., fluconazole, omeprazole).
* **CYP2C19 Inducers:** Decreased clobazam levels (e.g., rifampin).
* **CYP3A4 Inducers:** Decreased clobazam levels (e.g., carbamazepine, phenytoin).
* **Orlistat:** May reduce the absorption of clobazam.
## Monitoring
* Monitor for efficacy (seizure frequency and severity).
* Monitor for adverse effects, especially somnolence, behavioral changes, and signs of severe skin reactions.
* Monitor for signs of withdrawal if discontinuation is planned.
## Clinical Pearls
* Clobazam is a Schedule IV controlled substance.
* Initiate therapy with a low dose and titrate slowly to minimize adverse effects.
* Abrupt discontinuation can lead to withdrawal symptoms, including seizures. Taper the dose gradually.
* Clobazam can cause dose-related CNS depression. Advise patients to avoid activities requiring mental alertness until they know how the drug affects them.
* The active metabolite, N-desmethylclobazam (norclobazam), contributes to the therapeutic effect and has a longer half-life.
***
**Disclaimer:** This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and relevant guidelines before making treatment decisions.
